A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Purpose
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
Condition
- Crohn's Disease
Eligibility
- Eligible Ages
- Between 15 Years and 80 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Diagnosis of CD for at least 3 months prior to baseline - Confirmed diagnosis of moderate to severe CD as assessed by SF, AP score, and SES-CD - Demonstrated intolerance, loss of response or inadequate response to conventional or to biologic therapy for CD - If female, subject must meet the contraception recommendations
Exclusion Criteria
- Have a current diagnosis of ulcerative colitis, inflammatory bowel disease-unclassified (IBD-U) (formerly known as indeterminate colitis) or short bowel syndrome - Currently have or are suspected to have an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained, adequately treated and resolved at least 3 weeks prior to baseline or 8 weeks prior to baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery - Have a stoma, ileoanal pouch or ostomy - Have had a bowel resection within 6 months, or any kind of intra-abdominal or extra abdominal surgery within 3 months of baseline - Have ever received any monoclonal antibodies binding IL-23
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Placebo Comparator Placebo |
Participants received Placebo intravenously (IV) or subcutaneously (SC) every 4 weeks (Q4W). Any participant in the placebo arm who was considered a non-responder at Week 12 received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W for the remainder of the study. Nonresponse is defined as failing to achieve at least a 30% decrease in stool frequency (SF) and/or abdominal pain (AP) and be no worse than baseline. |
|
Experimental 300 mg Mirikizumab |
Participants received 900 milligrams (mg) Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W |
|
Active Comparator 90 mg Ustekinumab |
Participants received 6 mg/kg Ustekinumab IV for one dose, then 90 mg SC every 8 weeks (Q8W) |
|
Experimental 300 mg Mirikizumab (Adolescents) |
Participants received open label 900 mg Mirikizumab IV for 3 doses, then 300 mg SC Q4W |
|
More Details
- Status
- Completed
- Sponsor
- Eli Lilly and Company